ReviewExtracellular vesicles and circulating nucleic acids2026
Biological properties and potential pathogenic mechanisms of oral bacterial-derived extracellular vesicles in oral and systemic diseases.
Review in Extracellular vesicles and circulating nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes the biological characteristics of oral bacterial extracellular vesicles (O-BEVs) and their proposed roles in disease pathogenesis. As nanosized lipid bilayer structures secreted by oral bacteria, O-BEVs encapsulate virulence factors, nucleic acids, and metabolites, enabling them to traverse biological barriers and modulate host cellular functions. Studies suggest that O-BEVs are involved in the progression of oral diseases, including periodontitis, dental caries, and oral cancer through mechanisms such as immune activation, tissue destruction, and cellular behavior modulation. Furthermore, O-BEVs can enter the systemic circulation. Through synergistic interactions among their protein, lipid, and nucleic acid components, O-BEVs activate inflammatory pathways and compromise barrier integrity, thereby contributing to the pathogenesis of systemic diseases, including Alzheimer's disease, atherosclerosis, diabetes mellitus, rheumatoid arthritis, adverse pregnancy outcomes, and osteoporosis. However, most current evidence derives from preclinical (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.